Treatment of primary and metastatic carcinoma
View Patent ↗Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ET B ) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
1. A method of treating a cholangiocarcinoma, comprising: administering a therapeutically effective amount of an endothelin B (ET B ) receptor agonist, wherein the ET B receptor agonist is IRL-1620, and a therapeutically effective amount of chemotherapeutic agent to a subject suffering from a cholangiocarcinoma; wherein administration results in a reduction in the size or in the growth of the cholangiocarcinoma, thereby treating the cholangiocarinoma.
2. The method of claim 1 , wherein the therapeutically effective amount of IRL-1620 is about 5 μg/m 2 to about 11 μg/m 2 .
3. The method of claim 1 , wherein the chemotherapeutic agent is docetaxel.
4. The method of claim 3 , wherein the therapeutically effective amount of docetaxel is about 60 mg/m 2 to about 75 mg/m 2 .
5. The method of claim 1 , wherein the cholangiocarcinoma is a metastatic cholangiocarcinoma.
6. The method of claim 1 , wherein the ET B receptor agonist and the chemotherapeutic agent are administered substantially simultaneously.
7. A method of treating a metastatic carcinoma, comprising administering a therapeutically effective amount of an endothelin B (ET B ) receptor agonist, wherein the ET B receptor agonist is IRL-1620, and a chemotherapeutic agent to a subject suffering from a metastatic carcinoma; wherein administration results in a reduction in the size or in the growth of the metastatic carcinoma, thereby treating the metastatic carcinoma, wherein the metastatic carcinoma is a prostate cancer, an ovarian cancer, a breast cancer or a cholangiocarcinoma.
8. The method of claim 7 wherein the therapeutically effective amount of IRL-1620 is about 5 μg/m 2 to about 11 μg/m 2 .
9. The method of claim 7 , wherein the chemotherapeutic agent is docetaxel.
10. The method of claim 9 , wherein the therapeutically effective amount of docetaxel is about 60 mg/m 2 to about 75 mg/m 2 .
11. The method of claim 9 , wherein the therapeutically effective amount of docetaxel is about 60 mg/m 2 .
12. A method of treating a transition cell urothelial carcinoma, comprising: administering a therapeutically effective amount of an endothelin B (ET B ) receptor agonist, wherein the ET B receptor agonist is IRL-1620, and a chemotherapeutic agent to a subject suffering from a transition cell urothelial carcinoma; wherein administration results in a reduction in the size or in the growth of the transition cell urothelial carcinoma, thereby treating the transition cell urothelial carcinoma.
13. The method of claim 12 , wherein the therapeutically effective amount of IRL-1620 is about 5 μg/m 2 to about 11 μg/m 2 .
14. The method of claim 12 wherein the chemotherapeutic agent is docetaxel.
15. The method of claim 14 , wherein the therapeutically effective amount of docetaxel is about 60 mg/m 2 to about 75 mg/m 2 .
16. The method of claim 14 , wherein the therapeutically effective amount of docetaxel is about 60 mg/m 2 .
17. The method of claim 14 , wherein the therapeutically effective amount of docetaxel is about 75 mg/m 2 .